NCT05879276View on ClinicalTrials.gov

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

PHASE3RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

March 16, 2027

Study Completion Date

March 16, 2027

Conditions
Cardiogenic Shock
Interventions
DRUG

Empagliflozin 10 MG

Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.

Trial Locations (8)

21000

NOT_YET_RECRUITING

CHU de Dijon Bourgogne, Dijon

25000

RECRUITING

CHU de Besançon, Besançon

51000

NOT_YET_RECRUITING

CHU Reims, Reims

54500

RECRUITING

CHRU de NANCY - réanimation médicale, Vandœuvre-lès-Nancy

RECRUITING

Chru Nancy - Usic, Vandœuvre-lès-Nancy

57000

RECRUITING

CHR Metz - Thionville, Ars-Laquenexy

59000

NOT_YET_RECRUITING

CHU Lille, Lille

67000

RECRUITING

Hôpitaux Universitaires de Strasbourg, Strasbourg

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER